JP7099685B2 - 入眠・睡眠維持改善用組成物、ストレス低減、リラックス向上用組成物、パフォーマンス、集中力向上用組成物、及び、休憩の効果向上、疲労回復促進用組成物 - Google Patents
入眠・睡眠維持改善用組成物、ストレス低減、リラックス向上用組成物、パフォーマンス、集中力向上用組成物、及び、休憩の効果向上、疲労回復促進用組成物 Download PDFInfo
- Publication number
- JP7099685B2 JP7099685B2 JP2017193127A JP2017193127A JP7099685B2 JP 7099685 B2 JP7099685 B2 JP 7099685B2 JP 2017193127 A JP2017193127 A JP 2017193127A JP 2017193127 A JP2017193127 A JP 2017193127A JP 7099685 B2 JP7099685 B2 JP 7099685B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- improving
- sleep
- effect
- rafuma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000694 effects Effects 0.000 title claims description 29
- 239000000203 mixture Substances 0.000 title claims description 23
- 238000011084 recovery Methods 0.000 title claims description 14
- 230000001737 promoting effect Effects 0.000 title claims description 7
- 230000000284 resting effect Effects 0.000 title claims description 7
- 238000012423 maintenance Methods 0.000 title description 10
- 230000001603 reducing effect Effects 0.000 title description 7
- 230000002040 relaxant effect Effects 0.000 title description 7
- 239000004480 active ingredient Substances 0.000 claims description 8
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims description 6
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 claims description 3
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 claims description 3
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 claims description 3
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 claims description 3
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 claims description 3
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 claims description 3
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 230000000994 depressogenic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000006872 improvement Effects 0.000 description 10
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 235000013305 food Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000185686 Apocynum venetum Species 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000010792 Chromogranin A Human genes 0.000 description 2
- 108010038447 Chromogranin A Proteins 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 230000001814 effect on stress Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000005641 methacryl group Chemical group 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017193127A JP7099685B2 (ja) | 2017-10-02 | 2017-10-02 | 入眠・睡眠維持改善用組成物、ストレス低減、リラックス向上用組成物、パフォーマンス、集中力向上用組成物、及び、休憩の効果向上、疲労回復促進用組成物 |
| US15/938,618 US20190099463A1 (en) | 2017-10-02 | 2018-03-28 | Composition for improving sleep onset and sleep maintenance, composition for reducing stress and improving relaxation, composition for improving performance and concentration, and composition for improving resting effect and promoting recovery from fatigue |
| US17/085,148 US20210046136A1 (en) | 2017-10-02 | 2020-10-30 | Method for improving sleep onset and sleep maintenance, method for reducing stress and improving relaxation, method for improving performance and concentration, and method for improving resting effect and promoting recovery from fatigue |
| JP2021138730A JP2021181498A (ja) | 2017-10-02 | 2021-08-27 | 入眠・睡眠維持改善用組成物、ストレス低減、リラックス向上用組成物、パフォーマンス、集中力向上用組成物、及び、休憩の効果向上、疲労回復促進用組成物 |
| US17/870,951 US20220354914A1 (en) | 2017-10-02 | 2022-07-22 | Method for improving sleep onset and sleep maintenance, method for reducing stress and improving relaxation, method for improving performance and concentration, and method for improving resting effect and promoting recovery from fatigue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017193127A JP7099685B2 (ja) | 2017-10-02 | 2017-10-02 | 入眠・睡眠維持改善用組成物、ストレス低減、リラックス向上用組成物、パフォーマンス、集中力向上用組成物、及び、休憩の効果向上、疲労回復促進用組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021138730A Division JP2021181498A (ja) | 2017-10-02 | 2021-08-27 | 入眠・睡眠維持改善用組成物、ストレス低減、リラックス向上用組成物、パフォーマンス、集中力向上用組成物、及び、休憩の効果向上、疲労回復促進用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019064969A JP2019064969A (ja) | 2019-04-25 |
| JP7099685B2 true JP7099685B2 (ja) | 2022-07-12 |
Family
ID=65897060
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017193127A Active JP7099685B2 (ja) | 2017-10-02 | 2017-10-02 | 入眠・睡眠維持改善用組成物、ストレス低減、リラックス向上用組成物、パフォーマンス、集中力向上用組成物、及び、休憩の効果向上、疲労回復促進用組成物 |
| JP2021138730A Pending JP2021181498A (ja) | 2017-10-02 | 2021-08-27 | 入眠・睡眠維持改善用組成物、ストレス低減、リラックス向上用組成物、パフォーマンス、集中力向上用組成物、及び、休憩の効果向上、疲労回復促進用組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021138730A Pending JP2021181498A (ja) | 2017-10-02 | 2021-08-27 | 入眠・睡眠維持改善用組成物、ストレス低減、リラックス向上用組成物、パフォーマンス、集中力向上用組成物、及び、休憩の効果向上、疲労回復促進用組成物 |
Country Status (2)
| Country | Link |
|---|---|
| US (3) | US20190099463A1 (enExample) |
| JP (2) | JP7099685B2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025009025A1 (ja) * | 2023-07-03 | 2025-01-09 | 株式会社常磐植物化学研究所 | 月経に伴う不定愁訴、気分の落ち込み、集中力の低下、社交と日常活動への意欲の低下、自律神経の乱れ、痛み、コントロール、睡眠の質の低下を改善する組成物。 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737085B2 (en) * | 2000-11-01 | 2004-05-18 | Tokiwa Phytochemical Co., Ltd. | Apocynum venetum extract for use as antidepressant |
| CN105010667B (zh) * | 2015-07-05 | 2018-07-10 | 阿勒泰戈宝茶股份有限公司 | 助眠罗布麻茶及其制备方法 |
| JP6127169B2 (ja) * | 2016-02-15 | 2017-05-10 | 三基商事株式会社 | 睡眠改善剤 |
-
2017
- 2017-10-02 JP JP2017193127A patent/JP7099685B2/ja active Active
-
2018
- 2018-03-28 US US15/938,618 patent/US20190099463A1/en not_active Abandoned
-
2020
- 2020-10-30 US US17/085,148 patent/US20210046136A1/en not_active Abandoned
-
2021
- 2021-08-27 JP JP2021138730A patent/JP2021181498A/ja active Pending
-
2022
- 2022-07-22 US US17/870,951 patent/US20220354914A1/en not_active Abandoned
Non-Patent Citations (3)
| Title |
|---|
| FOOD STYLE 21, 2014, Vol. 18, No. 2, p. 22-24 |
| うつ病患者の回復過程における改善の認識，川崎医療福祉学会誌，2006年，Vol. 16, No. 1，p. 91-99 |
| 内田クレペリン精神検査を用いた就労判定に関する試み，日本職業・災害医学会会誌，2014年，Vol. 62，p. 161-166 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220354914A1 (en) | 2022-11-10 |
| JP2019064969A (ja) | 2019-04-25 |
| US20190099463A1 (en) | 2019-04-04 |
| JP2021181498A (ja) | 2021-11-25 |
| US20210046136A1 (en) | 2021-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101789424B1 (ko) | 구기자를 포함하는 수면장애 개선용 한방조성물 및 그 제조방법 | |
| JP2012025718A (ja) | 経口毛穴改善剤 | |
| US20230124668A1 (en) | Psychological fatigue preventer or improver | |
| JP7099685B2 (ja) | 入眠・睡眠維持改善用組成物、ストレス低減、リラックス向上用組成物、パフォーマンス、集中力向上用組成物、及び、休憩の効果向上、疲労回復促進用組成物 | |
| JP5704292B2 (ja) | 茶葉抽出組成物 | |
| JPWO2018016455A1 (ja) | 滋養強壮剤 | |
| JP2008214299A (ja) | パパイヤおよび白花蛇舌草の水溶性抽出成分を含む癌の予防、治療または改善のための組成物 | |
| KR20180044793A (ko) | 항피로 식품 조성물 및 항피로제 | |
| JP5688233B2 (ja) | Ｔａｒｃ産生抑制剤 | |
| JP2020188755A (ja) | 脳機能改善用食品組成物、脳機能改善剤、脳由来神経栄養因子増加用食品組成物、ストレスホルモン分泌抑制用食品組成物、脳由来神経栄養因子増加剤及びストレスホルモン分泌抑制剤 | |
| JP4787908B1 (ja) | 経口更年期症状改善剤 | |
| JP2006143664A (ja) | 自律神経失調症に伴う不定愁訴の改善剤 | |
| KR20130028261A (ko) | 감태 추출물 또는 이로부터 추출한 플로로글루시놀 화합물을 포함하는 파킨슨 질환의 예방 또는 치료용 조성물 | |
| CN110325195A (zh) | 脂肪细胞分化抑制剂、用于抑制脂肪细胞分化的食品组合物及脂肪细胞分化抑制剂的制造方法 | |
| JP2012031132A (ja) | 疲労改善組成物 | |
| KR102208654B1 (ko) | Tph1 유전자, ddc 유전자 및/또는 aanat 유전자의 발현을 조절하기 위한 바나나 껍질 추출물을 포함하는 조성물 | |
| JP2018154610A (ja) | Ｐｄｅ５活性阻害剤 | |
| EP3417867B1 (en) | Composition containing medicinal herb extract as active ingredient for preventing, alleviating, or treating stress or depression | |
| JP7498993B1 (ja) | 月経に伴う不定愁訴、気分の落ち込み、集中力の低下、社交と日常活動への意欲の低下、自律神経の乱れ、痛み、コントロール、睡眠の質の低下を改善する組成物。 | |
| JP2024111715A (ja) | 大気汚染による障害の予防用食品組成物及び大気汚染による障害の予防剤 | |
| KR102323577B1 (ko) | 부채마와 백년초의 혼합추출물을 포함하는 우울증 예방 또는 치료용 조성물 | |
| Flanary | The quest to extend life and overcome aging and death: past, present, and future attempts | |
| JP6873452B2 (ja) | 食品組成物 | |
| JP2019034902A (ja) | 組成物 | |
| Latifi et al. | Effects of plant-based beverage consumption on serum levels of thyroid hormones: Plant-based beverage and thyroid hormones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180328 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200518 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210428 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210628 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210827 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220202 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220621 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220623 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7099685 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |